17 alpha-hydroxylase deficiency prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Iqra Qamar (talk | contribs) |
||
(7 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{17 alpha-hydroxylase deficiency}} | {{17 alpha-hydroxylase deficiency}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{MJ}} | ||
==Overview== | ==Overview== | ||
Prenatal diagnosis of 17 alpha-hydroxylase deficiency is | [[Prenatal diagnosis]] of 17 alpha-hydroxylase deficiency is advised in order to prevent complications of the disease further in life. Prenatal administration of [[dexamethasone]], which is the drug of choice helps prevent complications. | ||
==Prevention== | ==Primary Prevention== | ||
* Prenatal diagnosis of 17 alpha-hydroxylase deficiency is | * [[Prenatal diagnosis]] of 17 alpha-hydroxylase deficiency is advised in order to prevent complications of the disease further in life. | ||
== | * [[Prenatal]] administration of [[dexamethasone]], which is the drug of choice helps prevent complications. | ||
*Testing modalities include: | |||
**[[Amniotic fluid]] testing. | |||
**[[Oligonucleotides|Oligonucleotide]] [[hybridization]] of [[deoxyribonucleic acid]] ([[DNA]]) which is obtained from [[Chorionic villus sampling|chorionic villus biopsies]]. In this method, [[fetal]] [[DNA]] is extracted from maternal blood through noninvasive methods.<ref name="pmid27378492">{{cite journal |vauthors=Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T |title=New developments in prenatal diagnosis of congenital adrenal hyperplasia |journal=J. Steroid Biochem. Mol. Biol. |volume=165 |issue=Pt A |pages=121–123 |year=2017 |pmid=27378492 |doi=10.1016/j.jsbmb.2016.06.016 |url=}}</ref> | |||
==References== | |||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 12:52, 23 October 2017
17 alpha-hydroxylase deficiency Microchapters |
Differentiating 17 alpha-hydroxylase deficiency from other Diseases |
Diagnosis |
Treatment |
Case Studies |
17 alpha-hydroxylase deficiency prevention On the Web |
American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency prevention |
Risk calculators and risk factors for 17 alpha-hydroxylase deficiency prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
Prenatal diagnosis of 17 alpha-hydroxylase deficiency is advised in order to prevent complications of the disease further in life. Prenatal administration of dexamethasone, which is the drug of choice helps prevent complications.
Primary Prevention
- Prenatal diagnosis of 17 alpha-hydroxylase deficiency is advised in order to prevent complications of the disease further in life.
- Prenatal administration of dexamethasone, which is the drug of choice helps prevent complications.
- Testing modalities include:
- Amniotic fluid testing.
- Oligonucleotide hybridization of deoxyribonucleic acid (DNA) which is obtained from chorionic villus biopsies. In this method, fetal DNA is extracted from maternal blood through noninvasive methods.[1]
References
- ↑ Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T (2017). "New developments in prenatal diagnosis of congenital adrenal hyperplasia". J. Steroid Biochem. Mol. Biol. 165 (Pt A): 121–123. doi:10.1016/j.jsbmb.2016.06.016. PMID 27378492.